A custom nanobody discovery platform turns a defined research or veterinary medicine need into a set of experimentally screened nanobody candidates. The process typically moves through target and antigen planning, library generation or immunization, candidate selection, sequence analysis, expression, and application-specific validation. At NBbiolab, we work with project teams to define these steps around the intended use, because a candidate that binds a purified protein is not automatically suitable for a diagnostic assay or other veterinary application. The most useful starting point is a clear target, a realistic assay context, and agreement on what evidence will count as success.
For more information, please visit our website.
Veterinary medicine projects may seek nanobodies for research reagents, diagnostic assay development, pathogen or biomarker detection, or exploratory therapeutic research. Each use imposes different requirements. A reagent for laboratory detection may prioritize consistent binding under assay conditions, while a candidate intended for further therapeutic development requires a broader assessment that discovery-stage binding alone cannot provide.
We recommend translating the goal into measurable project criteria before selecting a discovery route. These may include the target form to be recognized, expected sample matrix, related proteins to exclude, and the minimum evidence required to advance a candidate. This helps prevent a common mismatch: optimizing for a convenient screening assay rather than the application the buyer ultimately needs.
The first step is to specify the biological target and the reason for selecting it. Provide the target’s species and sequence information where available, relevant isoforms or variants, and the veterinary species or disease context involved. If the target is a pathogen protein, clarify whether the intended assay should recognize one strain, multiple strains, or a conserved region.
We also discuss how the nanobody will be used. Relevant details include whether the project is for research, assay development, or early-stage therapeutic exploration, and whether testing will involve purified protein, cultured material, or a specific sample type. These details guide antigen design, screening strategy, and the later validation plan.
The antigen is the material used to expose a discovery library or screen candidate binders. Depending on the target, it may be a purified protein, domain, peptide, or another suitable presentation. The chosen format should preserve the features that matter in the intended application, such as a binding site’s native conformation or accessibility.
We recommend discussing antigen quality, purity, expected structure, and available controls with the supplier before the project begins. For membrane-associated or complex targets, a short peptide may not represent the form encountered in a real assay. Where practical, planning for 2–3 antigen presentations—for example, different domains or formats—can help teams consider whether a result depends on one particular presentation; the appropriate number depends on the target and project scope.
Custom discovery commonly uses an immune library, a naïve library, or a synthetic or semi-synthetic library. An immune route can be considered when an appropriate immunization program and target are available; naïve and synthetic approaches provide alternative starting points without relying on the same project-specific immune response. The preferred route depends on target properties, project constraints, and the supplier’s available capabilities.
Nanobodies are commonly based on the variable domain of heavy-chain-only antibodies. A VHH domain is often around 110–130 amino acids in length and approximately 15 kDa in molecular mass, though individual sequences vary. These approximate figures describe the molecule class, not a guaranteed property or performance outcome for every discovered candidate.
Discovery teams use selection and screening methods to identify library members that bind the target under defined conditions. Depending on the platform, this may involve repeated enrichment followed by assays such as phage-based screening, ELISA, or other binding tests. The initial purpose is to find candidates for further investigation, not to declare a validated veterinary product.
Screen design matters. Screening only against a single purified antigen can favor candidates that bind that preparation but perform differently with a native target or in a complex sample. To reduce this risk, we encourage buyers to discuss negative controls, related proteins, antigen presentation, and whether the proposed screening format resembles the intended application.
Goto NBbiolab to know more.
Promising hits are typically examined at the sequence level and grouped to identify distinct candidate families. This step can help distinguish multiple unique binders from repeated recovery of closely related sequences. Teams may also review sequence features and expression considerations when deciding which candidates to move forward.
Prioritization should reflect the buyer’s goal rather than a single binding signal. A useful shortlist may consider binding strength under the screening conditions, specificity against relevant off-targets, sequence diversity, and practical expression. The exact assays and decision thresholds should be agreed in advance and reported with their limitations.
Selected sequences are expressed as recombinant proteins for follow-up testing. Validation may include confirming binding in an independent assay, checking specificity against related targets, and assessing performance in the intended assay format. For veterinary diagnostics, teams should consider whether the candidate recognizes the target from the relevant species or pathogen variant and whether the sample matrix could interfere with detection.
Validation is application-specific. A candidate that binds purified antigen in a laboratory assay may still need optimization for assay configuration, labeling, immobilization, or sample conditions. If the project concerns therapeutic research, binding data alone do not establish safety, efficacy, pharmacology, or suitability for animal use; those questions require separate development and evaluation.
Ask how the antigen will represent the target in the eventual assay. Confirm whether the project will use a full-length protein, a domain, a peptide, or another format, and ask what controls will help assess recognition of the relevant target form. For veterinary applications, discuss species and strain variation early rather than treating them as a late-stage issue.
Discovery proposals can differ in what they include, so specify the expected outputs. These might include candidate sequences, purified proteins, binding assay data, specificity testing, or a report describing methods and limitations. Ask which steps are included in the quoted scope and which may require a separate work package.
Set decision gates that reflect intended use. For example, a research reagent project may prioritize reproducible target binding, while a diagnostic development project may require evidence in the intended assay format and an assessment of relevant cross-reactivity. There is no universal cutoff that suits every target, so criteria should be tied to the project’s purpose and assay design.
At NBbiolab, we approach a custom nanobody discovery project as a sequence of decisions rather than a one-size-fits-all package. Our team can discuss target information, antigen options, discovery-route considerations, screening design, candidate deliverables, and application-oriented validation planning. The final scope depends on target feasibility, available materials, and the buyer’s requested evidence.
For veterinary medicine projects, we encourage customers to share the intended species, disease or research context, target variants, sample type, and planned assay format. These details help us identify questions that should be resolved before work begins and clarify what discovery-stage results can—and cannot—support. We do not treat candidate discovery as a substitute for product validation or regulatory review.
A custom nanobody discovery platform works by connecting target selection to candidate generation, screening, sequence-based prioritization, and validation in a relevant application context. The process is most effective when buyers define the target form, veterinary use case, controls, and advancement criteria before discovery starts. Binding is an important milestone, but it is not by itself proof of diagnostic or therapeutic readiness.
To assess fit, prepare your target details, intended use, available antigen materials, and preferred deliverables, then discuss them with a supplier. NBbiolab can review these inputs with your team and help scope a discovery and validation plan suited to your veterinary medicine project.
If you want to learn more, please visit our website Custom Nanobody Discovery Platform.